Genmab A/S Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance

COPENHAGEN, Denmark, Aug. 15, 2012 (GLOBE NEWSWIRE) -- Interim Report for the First Half 2012.

* DuoBody™ collaborations signed with Novartis and Janssen Biotech
* Daratumumab preliminary safety and efficacy data presented at ASCO and EHA
* Arzerra® first half net sales increased 37% over prior year
* 2012 guidance improved and H1 operating result and cash burn improved by 36% over 2011